SuperworthAptevo Therapeutics EPS APVO
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$5.31
- Fiscal year 2023
- −$940525.20
- −197% on the year before
Aptevo Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$5.31.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2023 | −$940525.20 | −197% |
| FY2022 | $972892.80 | n/a |
| FY2021 | −$3575088.00 | n/a |
| FY2020 | −$3012451.20 | n/a |
| FY2019 | −$9646876.80 | n/a |
| FY2018 | −$19528185.60 | −921% |
| FY2017 | $2379484.80 | n/a |
| FY2016 | −$45620467.20 | n/a |
| FY2015 | −$24041001.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$5.31 | n/a | n/a | |
| Q1 FY26 | −$6.41 | n/a | n/a | |
| Q3 FY25 | −$40.14 | n/a | n/a | |
| Q2 FY25 | −$151.29 | n/a | n/a | |
| Q1 FY25 | −$1581.81 | n/a | n/a | |
| Q3 FY24 | −$6441.48 | n/a | −$319503.96 | |
| Q2 FY24 | −$22265.28 | n/a | −$608233.68 | |
| Q1 FY24 | −$132555.60 | −157% | −$1304582.40 | |
| Q4 FY23 | −$158241.60 | n/a | −$940525.20 | |
| Q3 FY23 | −$295171.20 | n/a | −$1292173.20 | |
| Q2 FY23 | −$718614.00 | −122% | −$1876122.00 | |
| Q1 FY23 | $231501.60 | n/a | $2112818.40 |
Against its peers
Companies in Healthcare nearest Aptevo Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| APVOAptevo Therapeutics | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aptevo Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.